Evidence map›Paper›PMID 23303068›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013

The selective dopamine β-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior.

Jason P Schroeder, S Alisha Epps, Taylor W Grice, David Weinshenker

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.Progress in neuro-psychopharmacology & biological psychiatry · 2014
    Trial
  4. Article
  5. Article
  6. Article
  7. Exploring Nepicastat Activity: Beyond DβH.International journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jason P SchroederDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.
S Alisha Epps
Taylor W Grice
David Weinshenker
Emory University · US

Funding

Effects of voluntary exercise on reinstatement of cocaine seekingR01DA027535 · NIDA · EMORY UNIVERSITY · PI HOLMES, PHILIP V, WEINSHENKER, DAVID · 2010 to 2014
$1.9M
Genetic Analysis of a Rodent Model of Epilepsy and Depression Co-morbidityF31NS065663 · NINDS · EMORY UNIVERSITY · PI SMITH, SUNSHINE ALISHA EPPS · 2009 to 2012
$89k
NIDA NIH HHS DA027535NIDA NIH HHS R01 DA027535NINDS NIH HHS F31 NS065663NINDS NIH HHS NS065663
6 · The paper itself

Abstract

Although norepinephrine (NE) does not typically modulate cocaine self-administration under traditional schedules of reinforcement, it is required for different inducers of the reinstatement of cocaine-seeking behavior via activation of multiple adrenergic receptor subtypes. We predicted that blockade of NE synthesis would attenuate all known modalities of reinstatement and showed previously that the selective dopamine β-hydroxylase inhibitor, nepicastat, had no effect on either maintenance of operant cocaine self-administration maintained on a fixed-ratio 1 schedule or reinstatement of food seeking but did abolish cocaine-primed reinstatement. In the present series of studies, we first evaluated the dose-dependent effect of nepicastat (5, 50, or 100 mg/kg) on novelty-induced locomotor activity and found that it blunted exploration only at the highest dose. Next, we assessed the ability of nepicastat (50 mg/kg) to reduce breakpoint responding for cocaine on a progressive ratio schedule and reinstatement induced by drug-associated cues and stress. We found that nepicastat significantly lowered the breakpoint for cocaine, but not for regular chow or sucrose, and attenuated cue-, footshock-, and yohimbine-induced reinstatement. Combined, these results indicate that nepicastat can reduce the reinforcing properties of cocaine under a stringent schedule and can attenuate relapse-like behavior produced by cocaine, formerly cocaine-paired cues, and physiological and pharmacological stressors. Thus, nepicastat is one of those rare compounds that can reduce reinforced cocaine seeking as well as all three reinstatement modalities, while sparing exploratory behavior and natural reward seeking, making it a promising pharmacotherapy for cocaine addiction.

Indexed as

AnimalsCocaineCocaine-Related DisordersConditioning, OperantDopamine beta-HydroxylaseImidazolesMaleMotor ActivityRatsRats, Long-EvansRats, Sprague-DawleyThionesCocaineDopamine beta-HydroxylaseImidazolesnepicastatThiones

Identifiers

PMID23303068
PMCPMC3629392
OpenAlexW1967465620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.